ReviewFrontiers in cardiovascular medicine2026
The central role of mitochondrial pathology in sepsis-induced cardiomyopathy: from molecular mechanisms to clinical translation.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-induced cardiomyopathy (SIC) affects approximately 50% of severe sepsis patients, with mortality rates approaching 80%. This review examines mitochondrial pathology as the central orchestrator of SIC progression. Mitochondrial dysfunction encompasses impaired oxidative phosphorylation (OXPHOS), causing bioenergetic failure; mitochondrial DNA (mtDNA) release activating cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes, Toll-like receptor 9, and NOD-like receptor family pyrin domain containing 3 pathways; ETC dysfunction generating explosive reactive oxygen species (ROS); defective mitophagy leading to damaged mitochondria accumulation; and disturbed mitochondrial dynamics with excessive fission and suppressed fusion. Intercellular mitochondrial transfer through tunneling nanotubes (TNTs) exhibits paradoxical dual effects. Mitochondria-targeted antioxidants selectively accumulate within mitochondria to scavenge ROS and preserve membrane potential. Nrf2 activators enhance endogenous antioxidant defenses. Melatonin modulates mitochondrial function through Ripk3 inhibition. Clinical translation faces substantial obstacles due to sepsis heterogeneity, animal model limitations, and disease complexity. This review integrates mitochondrial biology, immunometabolism, and translational medicine to identify promising directions for improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.